EGFR and non-small cell lung carcinoma: Two clinical trials of combination therapy of platinum-doublet with IO (+/− angiogenesis inhibitor) for EGFR-mutant/ALK-rearranged NSCLC are ongoing (NCT:04042558: platinum-pemetrexed-atezolizumab +/− bevacizumab), along with the trial of (NCT:03991403: atezolizumab + bevacizumab + carboplatin + paclitaxel).